> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# FDA Moves Toward Easing Restrictions on Compounded Peptides
- URL: https://www.fdaweb.com/fda-moves-toward-easing-restrictions-on-compounded-peptides/
- Published: 2026-10-16T16:25:07.000Z
- Updated: 2026-10-16T16:25:07.000Z
- Author: David McFarland
- Tags: FDA Policy/General

The Trump administration is advancing an interim plan to allow compounding pharmacies to produce certain unapproved peptides despite FDA scientists' findings that available evidence is insufficient to establish their safety and effectiveness.

HHS 10/15 submitted an "interim access policy" for peptides to the White House Office of Management and Budget.

The proposal would reportedly allow pharmacies to temporarily compound certain peptides, including BPC-157, which is promoted for muscle growth and injury recovery. The approach would rely on FDA enforcement discretion rather than formally authorizing the substances for compounding, people familiar with the plan told NBC News. Details of the proposed policy have not been publicly released.

The potential policy would follow a July decision by FDA's Pharmacy Compounding Advisory Committee recommending that six of seven peptides under consideration be added to the agency's Section 503A Bulks List, despite FDA staff recommendations against all seven substances ([see earlier story](https://www.fdaweb.com/insufficient-data-on-7-peptides-for-potential-compounding-use-fda/)). Agency reviewers found limited clinical evidence supporting the safety and effectiveness of BPC-157, KPV, TB-500, MOTS-c, emideltide (DSIP), Semax and Epitalon.

The reviewers generally concluded that available evidence was insufficient to establish favorable benefit-risk profiles. FDA also identified concerns involving peptide impurities, potential immunogenicity and inadequate human safety data.

The advisory committee subsequently recommended inclusion of all seven substances except emideltide. Its recommendations were nonbinding and did not independently authorize their use in pharmacy compounding.

HHS secretary **Robert F. Kennedy Jr.** has advocated broader access to certain peptides, which have attracted increasing interest for potential applications involving wound healing, weight management, inflammation and longevity.